Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas
- PMID: 12865275
- PMCID: PMC1773762
- DOI: 10.1136/gut.52.8.1159
Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas
Abstract
Background and aims: We tested the hypothesis that the actual or predicted consequences of mutations in the cystic fibrosis transmembrane regulator gene correlate with the pancreatic phenotype and with measures of quantitative exocrine pancreatic function.
Methods: We assessed 742 patients with cystic fibrosis for whom genotype and clinical data were available. At diagnosis, 610 were pancreatic insufficient, 110 were pancreatic sufficient, and 22 pancreatic sufficient patients progressed to pancreatic insufficiency after diagnosis.
Results: We identified mutations on both alleles in 633 patients (85.3%), on one allele in 95 (12.8%), and on neither allele in 14 (1.9%). Seventy six different mutations were identified. The most common mutation was DeltaF508 (71.3%) followed by G551D (2.9%), G542X (2.3%), 621+1G-->T (1.2%), and W1282X (1.2%). Patients were categorized into five classes according to the predicted functional consequences of each mutation. Over 95% of patients with severe class I, II, and III mutations were pancreatic insufficient or progressed to pancreatic insufficiency. In contrast, patients with mild class IV and V mutations were consistently pancreatic sufficient. In all but four cases each genotype correlated exclusively with the pancreatic phenotype. Quantitative data of acinar and ductular secretion were available in 93 patients. Patients with mutations belonging to classes I, II, and III had greatly reduced acinar and ductular function compared with those with class IV or V mutations.
Conclusion: The predicted or known functional consequences of specific mutant alleles correlate with the severity of pancreatic disease in cystic fibrosis.
Figures

Similar articles
-
Analysis of exocrine pancreatic function in cystic fibrosis: one mild CFTR mutation does not exclude pancreatic insufficiency.Eur J Clin Invest. 2001 Sep;31(9):796-801. doi: 10.1046/j.1365-2362.2001.00876.x. Eur J Clin Invest. 2001. PMID: 11589722
-
[Relation between gene mutations and pancreatic exocrine function in patients with cystic fibrosis].Srp Arh Celok Lek. 2001 May-Jun;129 Suppl 1:6-9. Srp Arh Celok Lek. 2001. PMID: 15637983 Serbian.
-
The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype.Eur J Gastroenterol Hepatol. 2008 Mar;20(3):164-8. doi: 10.1097/MEG.0b013e3282f36d04. Eur J Gastroenterol Hepatol. 2008. PMID: 18301294
-
Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis.J Cyst Fibros. 2012 Sep;11(5):355-62. doi: 10.1016/j.jcf.2012.05.001. Epub 2012 Jun 2. J Cyst Fibros. 2012. PMID: 22658665 Review.
-
Exocrine pancreatic function in cystic fibrosis.Eur J Gastroenterol Hepatol. 1996 Aug;8(8):755-9. Eur J Gastroenterol Hepatol. 1996. PMID: 8864671 Review.
Cited by
-
Genetic modifiers of nutritional status in cystic fibrosis.Am J Clin Nutr. 2012 Dec;96(6):1299-308. doi: 10.3945/ajcn.112.043406. Epub 2012 Nov 7. Am J Clin Nutr. 2012. PMID: 23134884 Free PMC article.
-
Cystic Fibrosis-Related Diabetes (CFRD): Overview of Associated Genetic Factors.Diagnostics (Basel). 2021 Mar 22;11(3):572. doi: 10.3390/diagnostics11030572. Diagnostics (Basel). 2021. PMID: 33810109 Free PMC article. Review.
-
Diagnostic Accuracy of a Short Endoscopic Secretin Test in Patients With Cystic Fibrosis.Pancreas. 2015 Nov;44(8):1266-72. doi: 10.1097/MPA.0000000000000425. Pancreas. 2015. PMID: 26348465 Free PMC article.
-
Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation.Clin Transl Gastroenterol. 2017 Mar 16;8(3):e81. doi: 10.1038/ctg.2017.10. Clin Transl Gastroenterol. 2017. PMID: 28300821 Free PMC article.
-
Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis.Am J Respir Crit Care Med. 2013 Oct 1;188(7):807-12. doi: 10.1164/rccm.201307-1200OC. Am J Respir Crit Care Med. 2013. PMID: 23927602 Free PMC article.
References
-
- Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066–73. - PubMed
-
- Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059–65. - PubMed
-
- Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073–80. - PubMed
-
- Kartner N, Hanrahan JW, Jensen TJ, et al. Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance. Cell 1991;64:681–91. - PubMed
-
- di Sant’Agnese PA. Fibrocystic disease of the pancreas with normal or partial pancreatic function. Pediatrics 1955;15:683–96. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical